

David Polsky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2181331/publications.pdf>

Version: 2024-02-01

157
papers

7,991
citations

53751

45
h-index

49868

87
g-index

157
all docs

157
docs citations

157
times ranked

9308
citing authors

#	ARTICLE	IF	CITATIONS
1	Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. <i>Nature</i> , 2001, 409, 207-211.	13.7	901
2	Early Diagnosis of Cutaneous Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 2771.	3.8	506
3	Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 1814-1819.	3.3	506
4	Ultraviolet A and melanoma: A review. <i>Journal of the American Academy of Dermatology</i> , 2001, 44, 837-846.	0.6	379
5	Cooperative effects of <i>INK4a</i> and <i>ras</i> in melanoma susceptibility in vivo. <i>Genes and Development</i> , 1997, 11, 2822-2834.	2.7	366
6	The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. <i>Nature</i> , 2010, 468, 1105-1109.	13.7	345
7	Intra- and Inter-Tumor Heterogeneity of BRAFV600E Mutations in Primary and Metastatic Melanoma. <i>PLoS ONE</i> , 2012, 7, e29336.	1.1	250
8	Focus on melanoma. <i>Cancer Cell</i> , 2002, 2, 275-278.	7.7	225
9	The CASH (color, architecture, symmetry, and homogeneity) algorithm for dermoscopy. <i>Journal of the American Academy of Dermatology</i> , 2007, 56, 45-52.	0.6	203
10	Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2008, 14, 8302-8307.	3.2	193
11	Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. <i>Cancer Research</i> , 2003, 63, 3955-7.	0.4	177
12	Association of melanoma and neurocutaneous melanocytosis with large congenital melanocytic naevi-results from the NYU-LCMN registry. <i>British Journal of Dermatology</i> , 2005, 152, 512-517.	1.4	176
13	ABCDE—An Evolving Concept in the Early Detection of Melanoma. <i>Archives of Dermatology</i> , 2005, 141, 1032-4.	1.7	149
14	Oncogenes in melanoma. <i>Oncogene</i> , 2003, 22, 3087-3091.	2.6	107
15	Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 114-120.e2.	0.6	107
16	Meta-analysis of sentinel lymph node positivity in thin melanoma (≤ 1 mm). <i>Cancer</i> , 2009, 115, 869-879.	2.0	105
17	Frequent p16-Independent Inactivation of p14ARF in Human Melanoma. <i>Journal of the National Cancer Institute</i> , 2008, 100, 784-795.	3.0	94
18	HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. <i>Cancer Research</i> , 2001, 61, 7642-6.	0.4	94

#	ARTICLE	IF	CITATIONS
19	Role of radiologic imaging at the time of initial diagnosis of stage T1b–T3b melanoma. <i>Cancer</i> , 2007, 110, 1107-1114.	2.0	93
20	Reduction of ultraviolet transmission through cotton t-shirt fabrics with low ultraviolet protection by various laundering methods and dyeing: Clinical implications. <i>Journal of the American Academy of Dermatology</i> , 2001, 44, 767-774.	0.6	92
21	Noninvasive genomic detection of melanoma. <i>British Journal of Dermatology</i> , 2011, 164, 797-806.	1.4	92
22	New Systematic Therapies and Trends in Cutaneous Melanoma Deaths Among US Whites, 1986–2016. <i>American Journal of Public Health</i> , 2020, 110, 731-733.	1.5	91
23	A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates. <i>PLoS ONE</i> , 2010, 5, e15588.	1.1	90
24	High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas. <i>Cancer</i> , 2001, 92, 869-874.	2.0	89
25	Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. <i>Cancer</i> , 2011, 117, 1711-1720.	2.0	83
26	PTEN Expression in Melanoma: Relationship with Patient Survival, Bcl-2 Expression, and Proliferation. <i>Clinical Cancer Research</i> , 2005, 11, 5153-5157.	3.2	81
27	Changes in the presentation of nodular and superficial spreading melanomas over 35 years. <i>Cancer</i> , 2008, 113, 3341-3348.	2.0	78
28	The Diagnostic Performance of Expert Dermoscopists vs a Computer-Vision System on Small-Diameter Melanomas. <i>Archives of Dermatology</i> , 2008, 144, 476-82.	1.7	78
29	Vulvar nevi, melanosis, and melanoma: An epidemiologic, clinical, and histopathologic review. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 1241-1249.	0.6	77
30	The transcriptional repressor of p16/Ink4a, Id1, is up-regulated in early melanomas. <i>Cancer Research</i> , 2001, 61, 6008-11.	0.4	77
31	HDM2 Protein Overexpression and Prognosis in Primary Malignant Melanoma. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1803-1806.	3.0	74
32	Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy. <i>Journal of the National Cancer Institute</i> , 2019, 111, 180-188.	3.0	74
33	Towards Automated Melanoma Detection With Deep Learning: Data Purification and Augmentation. , 2019, , .		70
34	De Novo vs Nevus-Associated Melanomas: Differences in Associations With Prognostic Indicators and Survival. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw121.	3.0	67
35	Sensitivity of plasma BRAF ^{mutant} and NRAS ^{mutant} cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression. <i>Molecular Oncology</i> , 2016, 10, 157-165.	2.1	63
36	Phosphorylated 4E-BP1 Is Associated with Poor Survival in Melanoma. <i>Clinical Cancer Research</i> , 2009, 15, 2872-2878.	3.2	62

#	ARTICLE	IF	CITATIONS
37	Detection of melanomas in patients followed up with total cutaneous examinations, total cutaneous photography, and dermoscopy. <i>Journal of the American Academy of Dermatology</i> , 2004, 50, 15-20.	0.6	60
38	Prognostic Gene Expression Profiling in Cutaneous Melanoma. <i>JAMA Dermatology</i> , 2020, 156, 1004.	2.0	59
39	Clinical significance of BRAF mutations in metastatic melanoma. <i>Journal of Translational Medicine</i> , 2004, 2, 46.	1.8	58
40	Dermoscopy Key Points: Recommendations from the International Dermoscopy Society. <i>Dermatology</i> , 2007, 214, 3-5.	0.9	58
41	More Skin, More Sun, More Tan, More Melanoma. <i>American Journal of Public Health</i> , 2014, 104, e92-e99.	1.5	58
42	Integrative Genomics Identifies Molecular Alterations that Challenge the Linear Model of Melanoma Progression. <i>Cancer Research</i> , 2011, 71, 2561-2571.	0.4	57
43	MC1R variants as melanoma risk factors independent of at-risk phenotypic characteristics: a pooled analysis from the M-SKIP project. <i>Cancer Management and Research</i> , 2018, Volume 10, 1143-1154.	0.9	57
44	Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. <i>Lancet Oncology</i> , The, 2021, 22, 370-380.	5.1	57
45	Utility of Lesion Diameter in the Clinical Diagnosis of Cutaneous Melanoma. <i>Archives of Dermatology</i> , 2008, 144, 469-74.	1.7	52
46	Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma. <i>Cancer</i> , 2002, 95, 634-640.	2.0	50
47	Development of Novel Mutation-Specific Droplet Digital PCR Assays Detecting TERT Promoter Mutations in Tumor and Plasma Samples. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 274-285.	1.2	46
48	Agreement of Dermatopathologists in the Evaluation of Clinically Difficult Melanocytic Lesions: How Golden Is the 'Gold Standard'? <i>Dermatology</i> , 2012, 224, 51-58.	0.9	45
49	Skin cancer risk in <i>BRCA1/2</i> mutation carriers. <i>British Journal of Dermatology</i> , 2015, 172, 1498-1506.	1.4	45
50	Altered N-myc Downstream-Regulated Gene 1 Protein Expression in African-American Compared with Caucasian Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2004, 10, 222-227.	3.2	40
51	Detection of Mutant BRAF Alleles in the Plasma of Patients with Metastatic Melanoma. <i>Journal of Molecular Diagnostics</i> , 2007, 9, 178-183.	1.2	40
52	â€œFat fingers:â€A clue in the dermoscopic diagnosis ofâ€seborrheic keratoses. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, 1089-1091.	0.6	39
53	Acral melanocytic lesions in the United States: Prevalence, awareness, and dermoscopic patterns in skin-of-color and non-Hispanic white patients. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 724-730.e1.	0.6	39
54	Association of <i>MDM2</i> SNP309, Age of Onset, and Gender in Cutaneous Melanoma. <i>Clinical Cancer Research</i> , 2009, 15, 2573-2580.	3.2	36

#	ARTICLE	IF	CITATIONS
55	Analysis of the Benign to Malignant Ratio of Lesions Biopsied by a General Dermatologist Before and After the Adoption of Dermoscopy. Archives of Dermatology, 2011, 146, 343-4.	1.7	36
56	Mitotic Rate in Melanoma. American Journal of Surgical Pathology, 2013, 37, 882-889.	2.1	36
57	Botulinum Toxin-A for the Treatment of Raynaud Syndrome. Archives of Dermatology, 2012, 148, 426.	1.7	34
58	Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. American Journal of Translational Research (discontinued), 2009, 1, 35-43.	0.0	33
59	Melanoma Prognosis: Accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition. Journal of the National Cancer Institute, 2020, 112, 921-928.	3.0	32
60	Melanoma risk loci as determinants of melanoma recurrence and survival. Journal of Translational Medicine, 2013, 11, 279.	1.8	30
61	Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma. Journal of Translational Medicine, 2007, 5, 2.	1.8	29
62	Technological advances for the detection of melanoma. Journal of the American Academy of Dermatology, 2020, 83, 983-992.	0.6	29
63	The importance of dedicated dermoscopy training during residency: A survey of US dermatology chief residents. Journal of the American Academy of Dermatology, 2013, 68, 1000-1005.	0.6	27
64	Evaluation of germline CDKN2A, ARF, CDK4, PTEN, and BRAF alterations in atypical mole syndrome. Clinical and Experimental Dermatology, 2005, 30, 68-70.	0.6	23
65	Neutrophilic eccrine hidradenitis masquerading as facial cellulitis. Journal of the American Academy of Dermatology, 2007, 56, 693-696.	0.6	21
66	Mole Mapping for Management of Pigmented Skin Lesions. Dermatologic Clinics, 2017, 35, 439-445.	1.0	21
67	CASH Algorithm for Dermoscopy Revisited. Archives of Dermatology, 2008, 144, 554-5.	1.7	20
68	Technological advances for the detection of melanoma. Journal of the American Academy of Dermatology, 2020, 83, 996-1004.	0.6	20
69	Impact of COVID-19 on melanoma diagnosis. Melanoma Research, 2021, 31, 280-281.	0.6	18
70	Suppression of H-2b-associated resistance to Friend erythroleukemia virus by a class I gene from the H-2d major histocompatibility complex haplotype.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 9243-9247.	3.3	17
71	HMO penetration and the geographic mobility of practicing physicians. Journal of Health Economics, 2000, 19, 793-809.	1.3	17
72	A High Proliferative Index of Recurrent Melanoma Is Associated with Worse Survival. Oncology, 2011, 80, 181-187.	0.9	17

#	ARTICLE	IF	CITATIONS
73	Genetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma. <i>Journal of Medical Genetics</i> , 2015, 52, 231-239.	1.5	17
74	Shedding of Distinct Cryptic Collagen Epitope (HU177) in Sera of Melanoma Patients. <i>Clinical Cancer Research</i> , 2008, 14, 6253-6258.	3.2	16
75	Association of Melanocortin-1 Receptor Variants with Pigmentary Traits in Humans: A Pooled Analysis from the M-Skip Project. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1914-1917.	0.3	16
76	MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 332-342.	2.7	16
77	Impact of Age on the Management of Primary Melanoma Patients. <i>Oncology</i> , 2013, 85, 173-181.	0.9	14
78	TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1609-1618.e7.	0.3	14
79	Development of a Melanoma Risk Prediction Model Incorporating MC1R Genotype and Indoor Tanning Exposure: Impact of Mole Phenotype on Model Performance. <i>PLoS ONE</i> , 2014, 9, e101507.	1.1	14
80	Impact of initial stage on metastatic melanoma survival. <i>Melanoma Research</i> , 2019, 29, 281-288.	0.6	12
81	Tinea versicolor associated with etanercept therapy. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, S99-S100.	0.6	11
82	Cyclo-oxygenase-2 inhibitors for chemoprevention of nonmelanoma skin cancer: Is there a role for these agents?. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 173-176.	0.6	11
83	Plasma cell-free circulating tumor DNA (ctDNA) detection in longitudinally followed glioblastoma patients using TERT promoter mutation-specific droplet digital PCR assays. <i>Journal of Clinical Oncology</i> , 2019, 37, 2026-2026.	0.8	11
84	Nucleofection is a highly effective gene transfer technique for human melanoma cell lines. <i>Experimental Dermatology</i> , 2008, 17, 405-411.	1.4	10
85	Assessing the clinical utility of measuring Insulin-like Growth Factor Binding Proteins in tissues and sera of melanoma patients. <i>Journal of Translational Medicine</i> , 2008, 6, 70.	1.8	10
86	Impact of Socioeconomic Status and Ethnicity on Melanoma Presentation and Recurrence in Caucasian Patients. <i>Oncology</i> , 2016, 90, 79-87.	0.9	10
87	Acral Lentiginous Melanoma of the Foot Misdiagnosed as a Traumatic Ulcer. <i>Journal of the American Podiatric Medical Association</i> , 2015, 105, 189-194.	0.2	9
88	Late-Stage Melanoma in New York State: Associations with Socioeconomic Factors and Healthcare Access at the County Level. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1699-1706.e7.	0.3	9
89	Development of a melanoma risk prediction model incorporating MC1R genotype and indoor tanning exposure. <i>Journal of Clinical Oncology</i> , 2012, 30, 8574-8574.	0.8	9
90	Mutational Heterogeneity in Melanoma: An Inconvenient Truth. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2913-2918.	0.3	8

#	ARTICLE	IF	CITATIONS
91	Real-world outcomes of melanoma surveillance using the MoleMap NZ telemedicine platform. Journal of the American Academy of Dermatology, 2021, 85, 596-603.	0.6	8
92	Dermoscopic features of a solitary fibrofolliculoma on the left cheek. Journal of the American Academy of Dermatology, 2017, 76, S8-S9.	0.6	7
93	Association between Ki-67 expression and clinical outcomes among patients with clinically node-negative, thick primary melanoma who underwent nodal staging. Journal of Surgical Oncology, 2018, 118, 150-156.	0.8	7
94	Validation of Circulating Tumor DNA Assays for Detection of Metastatic Melanoma. Methods in Molecular Biology, 2020, 2055, 155-180.	0.4	7
95	Associations between TERT Promoter Mutations and Survival in Superficial Spreading and Nodular Melanomas in a Large Prospective Patient Cohort. Journal of Investigative Dermatology, 2022, 142, 2733-2743.e9.	0.3	7
96	Altered patterns of RB expression define groups of soft tissue sarcoma patients with distinct biological and clinical behavior. Histology and Histopathology, 2006, 21, 743-52.	0.5	7
97	Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care. Oncology, 2017, 93, 164-176.	0.9	6
98	Immunomodulatory germline variation associated with the development of multiple primary melanoma (MPM). Scientific Reports, 2019, 9, 10173.	1.6	6
99	MC1R variants and cutaneous melanoma risk according to histological type, body site, and Breslow thickness: a pooled analysis from the M-SKIP project. Melanoma Research, 2020, 30, 500-510.	0.6	6
100	Germline genetic determinants of immunotherapy response in metastatic melanoma.. Journal of Clinical Oncology, 2014, 32, 3004-3004.	0.8	6
101	Sustaining the Rheumatology Research Enterprise. Arthritis Care and Research, 2015, 67, 1187-1190.	1.5	5
102	A prospective study evaluating the utility of a 2-mm biopsy margin for complete removal of histologically atypical (dysplastic) nevi. Journal of the American Academy of Dermatology, 2017, 77, 1096-1099.	0.6	5
103	Dermoscopy Proficiency Expectations for US Dermatology Resident Physicians. JAMA Dermatology, 2021, 157, 189.	2.0	4
104	Melanoma surveillance for high-risk patients via telemedicine: Examination of real-world data from an integrated store-and-forward total body photography and dermoscopy service. Journal of the American Academy of Dermatology, 2022, 86, 191-192.	0.6	4
105	MC1R variants in relation to naevi in melanoma cases and controls: a pooled analysis from the M-SKIP project. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e135-e138.	1.3	3
106	Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasis. BMC Cancer, 2015, 15, 926.	1.1	2
107	Bone metastasis to predict treatment response rate and overall survival of patients with metastatic melanoma.. Journal of Clinical Oncology, 2018, 36, e21585-e21585.	0.8	2
108	Cell-Free DNA in Dermatology Research. Journal of Investigative Dermatology, 2022, 142, 1523-1528.e1.	0.3	2

#	ARTICLE	IF	CITATIONS
109	Polarized light dermoscopy to aid in the diagnosis of new pink lesions in an amelanotic melanoma survivor. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, e197-e199.	0.6	1
110	Acral Melanoma: A Patient's Experience and Physician's Commentary. <i>Dermatology and Therapy</i> , 2018, 8, 503-507.	1.4	1
111	Comment on "Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma". <i>Journal of the American Academy of Dermatology</i> , 2018, 79, e53-e54.	0.6	1
112	A phase II trial of BAY 439006 in metastatic melanoma with molecularly characterized B-Raf status. <i>Journal of Clinical Oncology</i> , 2006, 24, 8046-8046.	0.8	1
113	Tumor heterogeneity: Evidence from BRAF V600E mutation detection. <i>Journal of Clinical Oncology</i> , 2008, 26, 20022-20022.	0.8	1
114	Circulating tumor DNA (ctDNA) kinetics to predict survival in patients (pts) with unresectable or metastatic melanoma treated with dabrafenib (D) or D + trametinib (T).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9510-9510.	0.8	1
115	Detection of BRAF kinase mutations in melanoma, ovarian, and prostate carcinomas: Evidence for tumor heterogeneity in clinical samples. <i>Journal of Clinical Oncology</i> , 2009, 27, 11031-11031.	0.8	1
116	Abstract 743: Detection of TERT C228T and C250T promoter mutations in melanoma tumor and plasma samples using novel mutation-specific droplet digital PCR assays. , 2017, , .		1
117	Abstract 5534: Analysis of TERT mutant circulating tumor DNA as a potential biomarker of disease activity in patients with unresectable stage III/IV melanoma receiving immuno-oncology therapies. , 2018, , .		1
118	Abstract 2239: Analysis of nucleosomal DNA as an extraction control for plasma-based circulating tumor DNA assays. , 2019, , .		1
119	In Consideration of the E in the Melanoma ABCDE Mnemonic"Reply. <i>Archives of Dermatology</i> , 2006, 142, 529.	1.7	0
120	Association Between Thin Melanomas and Atypical Nevi in Middle-aged and Older Men Possibly Attributable to Heightened Patient Awareness. <i>Archives of Dermatology</i> , 2009, 145, 1457-8.	1.7	0
121	Examining the scalp for melanoma? Try a blow dryer. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, e211.	0.6	0
122	214 A growing mortality epidemic among white men ages 50+: Time to find intersections for a targeted national melanoma screening program. <i>Journal of Investigative Dermatology</i> , 2017, 137, S36.	0.3	0
123	Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM). <i>Annals of Oncology</i> , 2018, 29, viii21.	0.6	0
124	An irregular black patch on the nail plate. <i>JAAD Case Reports</i> , 2020, 6, 1069-1071.	0.4	0
125	Utility of confocal microscopy in the management of lentigo maligna and lentigo maligna melanoma. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1736-1737.	0.6	0
126	Melanoma origins: data from early-stage tumours supports de novo and naevus-associated melanomas as distinct subtypes. <i>British Journal of Dermatology</i> , 2021, 185, 9-10.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Clinical relevance of neutral endopeptidase overexpression in melanoma. Journal of Clinical Oncology, 2006, 24, 8028-8028.	0.8	0
128	Evaluation of the melanocortin-1-receptor gene in melanoma predisposition, progression, and recurrence. Journal of Clinical Oncology, 2009, 27, 9018-9018.	0.8	0
129	Developing genetic markers for melanoma risk assessment. Journal of Clinical Oncology, 2009, 27, 9046-9046.	0.8	0
130	The unique molecular signatures of nodular and superficial spreading melanoma. Journal of Clinical Oncology, 2009, 27, 9047-9047.	0.8	0
131	Dysplastic Nevi. , 2011, , 231-245.		0
132	Prognostic value of mitosis-specific antibodies and computer image analysis in calculating mitotic rate in melanoma.. Journal of Clinical Oncology, 2012, 30, e19003-e19003.	0.8	0
133	Abstract 2288: Improving melanoma risk prediction among individuals with low-risk mole phenotypes.. , 2013, , .		0
134	Impact of age on treatment of primary melanoma patients.. Journal of Clinical Oncology, 2013, 31, 9054-9054.	0.8	0
135	Analysis of plasma-based BRAF and NRAS mutation detection in patients with stage III and IV melanoma.. Journal of Clinical Oncology, 2013, 31, 9023-9023.	0.8	0
136	The genetic variants in interleukin locus at 1q32.1 as markers of melanoma survival.. Journal of Clinical Oncology, 2014, 32, 9094-9094.	0.8	0
137	Droplet digital PCR monitoring of BRAF and NRAS plasma DNA as biomarkers of treatment response in stage IV melanoma.. Journal of Clinical Oncology, 2014, 32, 9019-9019.	0.8	0
138	Abstract 2847: Quantitative assessment of circulating BRAF DNA in stage IV melanoma patients undergoing BRAF inhibitor treatment. , 2014, , .		0
139	The impact of primary melanoma histotype on overall survival and response to immunotherapy.. Journal of Clinical Oncology, 2015, 33, e20078-e20078.	0.8	0
140	Impact of socioeconomic status (SES) and ethnicity on melanoma presentation and recurrence in Caucasian patients.. Journal of Clinical Oncology, 2015, 33, e20098-e20098.	0.8	0
141	De novo versus nevus-associated melanomas: Differences in associations with prognostic indicators and survival.. Journal of Clinical Oncology, 2015, 33, 9025-9025.	0.8	0
142	Abstract A31: Association between TERT promoter mutations and BRAF/NRAS mutations in patients with primary and metastatic melanoma tumors. , 2015, , .		0
143	Abstract 4627: A novel computational re-analysis of published GWAS data suggests new risk loci for melanoma susceptibility. , 2015, , .		0
144	Abstract 4628: Analysis of melanoma GWAS data suggests specific risk loci influencing age of onset of melanoma. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
145	Metastatic melanoma outcomes in the era of commercially available targeted therapy and immunotherapy.. Journal of Clinical Oncology, 2016, 34, e21017-e21017.	0.8	0
146	Prognostic value of mitoses in thick primary melanoma.. Journal of Clinical Oncology, 2016, 34, e21046-e21046.	0.8	0
147	The impact of clinical stage at primary melanoma diagnosis on post-recurrence survival.. Journal of Clinical Oncology, 2016, 34, 9550-9550.	0.8	0
148	Analysis of TERT promoter mutations, polymorphisms, clinicopathologic features and recurrence-free survival in primary melanoma.. Journal of Clinical Oncology, 2016, 34, e21065-e21065.	0.8	0
149	Novel germline risk loci in familial melanoma (FM).. Journal of Clinical Oncology, 2017, 35, 1535-1535.	0.8	0
150	A 'melanoma mortality belt' of ten U.S. states with the highest melanoma mortality rates.. Journal of Clinical Oncology, 2017, 35, e21039-e21039.	0.8	0
151	Accelerated melanoma mortality rates among middle-aged white males with tumors of all thicknesses.. Journal of Clinical Oncology, 2017, 35, e21029-e21029.	0.8	0
152	Abstract 5531: Detection of co-occurring and potential resistance mutations in cell-free, circulating tumor DNA from patients with BRAF mutant metastatic melanoma undergoing treatment with BRAF-targeted therapies. , 2018, , .		0
153	Abstract 4704: Identification of melanoma mutational tumor heterogeneity using BRAF, NRAS and TERT-promoter mutation-detection assays. , 2019, , .		0
154	The ABCDEs of melanoma: an evolving concept. Journal of Drugs in Dermatology, 2005, 4, 399-401.	0.4	0
155	Differentiating Between Lead-Time Bias and True Survival Benefits When Discussing Racial and Ethnic Disparities in Melanoma. JAMA Dermatology, 2022, , .	2.0	0
156	Explaining differences in chemotherapy utilization in ovarian cancer between health service areas. Journal of Clinical Oncology, 2004, 22, 6005-6005.	0.8	0
157	Patient- and County-Level Factors Associated with Late-Stage Merkel Cell Carcinoma at Diagnosis. Journal of Investigative Dermatology, 2022, 142, 3113-3117.	0.3	0